Christopher Swann - Pacific Edge Chairman of the Board

PEB -- New Zealand Stock  

NZD 0.34  0.005  1.47%

  Chairman
Mr. Christopher John Swann was Independent Chairman of the Board of Pacific Edge Limited since February 1 2007. Mr. Swann is principal of T.D. Scott and Co. a Dunedin based accountancy and consulting firm. Mr. Swann was principal of the firm for 10 years. Mr. Swann is an experienced business advisor in various industries including the manufacturing publishing health and biotechnology sectors. He is currently manager of the New Zealand Seed Fund which has investment in four biotechnology companies including Pacific Edge. He also holds other directorships and is a member of the NZ Institute of Directors.
  Chairman Since 2007      
64 3 479 5800  http://www.pacificedge.co.nz

Management Efficiency

The company has return on total asset (ROA) of (66.91) % which means that it has lost $66.91 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (124.28) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 99K in total debt with debt to equity ratio (D/E) of 0.6 which is about average as compared to similar companies. Pacific Edge Limited has Current Ratio of 6.06 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 6 records

CHAIRMAN Since

Peter WilsonArvida Group Limited
N/A
Anthony CarterFisher Paykel Healthcare Corpor
2012
Antony CarterFisher Paykel Healthcare Corpor
2012
Neil CraigComvita Limited
2005
Alan BougenComvita Limited
N/A
Trevor JanesAbano Healthcare Group Limited
2018

Entity Summary

Pacific Edge Limited, a cancer diagnostic company, develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand and internationally. Pacific Edge Limited was founded in 2001 and is headquartered in Dunedin, New Zealand. Pacific Edge operates under Diagnostics Research classification in New Zealand and is traded on New Zealand Stock Exchange.Pacific Edge Limited (PEB) is traded on New Zealand Stock Exchange in New Zealand. It is located in Centre for Innovation and employs 2 people.

Pacific Edge Limited Leadership Team

Chris Gallaher, Independent Director
Parry Guilford, Chief Scientific Officer and Member of Scientific Advisory Board
Kate Rankin, CFO
N Kasabov, Head of Knowledge Engineering Discovery Research Institute (KEDRI)
Jimmy Suttie, COO
Christopher Swann, Chairman of the Board
David Darling, CEO and Executive Director
David Band, Independent Director
David Levison, Director
Charles Sitch, Independent Director
Brent Pownall, Commercial Director of Pacific Edge Diagnostics - New Zealand
Jackie Walker, CEO - Pacific Edge Diagnostics USA Ltd (PEDUSA)
Anatole Masfen, Director
Nikola Kasabov, Head of Knowledge Engineering Discovery Research Institute (KEDRI)
Bryan Williams, Independent Director

Stock Performance Indicators

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Price Transformation
Currently Active Assets on Macroaxis
CTL   
Purchased over 90 shares of
3 hours ago
Traded for 16.27
NLY   
Purchased over 90 shares of
3 hours ago
Traded for 10.07
CRM   
Purchased over 100 shares of
3 hours ago
Traded for 137.04
V   
Purchased over 100 shares of
3 hours ago
Traded for 132.67
MSFT   
Purchased over 100 shares of
3 hours ago
Traded for 103.3
Additionally take a look at Your Equity Center. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Search macroaxis.com